Anthera Pharmaceuticals, Inc.
ANTH · OTC
12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |
|---|---|---|---|---|
| Revenue | $0 | $145 | $3,185 | $0 |
| % Growth | -100% | -95.4% | – | – |
| Cost of Goods Sold | $281 | $46 | $31 | $22 |
| Gross Profit | -$281 | $99 | $3,154 | -$22 |
| % Margin | – | 68.1% | 99% | – |
| R&D Expenses | $28,594 | $46,251 | $30,860 | $21,839 |
| G&A Expenses | $7,938 | $11,071 | $7,568 | $6,620 |
| SG&A Expenses | $7,938 | $11,071 | $7,568 | $6,620 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$85 | $0 | $0 | $0 |
| Operating Expenses | $36,532 | $57,322 | $38,428 | $28,459 |
| Operating Income | -$36,432 | -$57,177 | -$35,243 | -$28,459 |
| % Margin | – | -39,432.4% | -1,106.5% | – |
| Other Income/Exp. Net | $9,558 | $1,654 | $23 | -$1,145 |
| Pre-Tax Income | -$26,874 | -$55,523 | -$35,220 | -$29,604 |
| Tax Expense | $0 | -$1,920 | -$308 | $0 |
| Net Income | -$16,935 | -$53,603 | -$34,912 | -$30,309 |
| % Margin | – | -36,967.6% | -1,096.1% | – |
| EPS | -1.65 | -10.38 | -7.84 | -11.13 |
| % Growth | 84.1% | -32.4% | 29.6% | – |
| EPS Diluted | -1.65 | -10.38 | -7.84 | -11.13 |
| Weighted Avg Shares Out | 10,278 | 5,164 | 4,454 | 2,722 |
| Weighted Avg Shares Out Dil | 10,278 | 5,164 | 4,454 | 2,722 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1,049 |
| Depreciation & Amortization | $281 | $266 | -$23 | $344 |
| EBITDA | -$26,593 | -$56,911 | -$34,958 | -$28,211 |
| % Margin | – | -39,249% | -1,097.6% | – |